After Multiple Failures, Teva Returns Laquinimod Rights to Active Biotech | BioSpace
Active Biotech - News, Articles etc. - European Pharmaceutical Review
Active Biotech regains rights of laquinimod from Teva
Teva Pharmaceutical Industries. Information about the issuer. (LEI 549300BAFGM4RC74ZJ94, SWIFT TEVPILITXXX). News and credit ratings. Tables with accounting and financial reports.
Teva posts positive phase 3 migraine data, plots FDA submission | Fierce Biotech
Active Biotech's partner Teva starts laquinimod clinical trial
Teva drops development of laquinimod - PharmaTimes
ANNUAL REPORT 2020 | ACTIVE BIOTECH AB
Teva, Active Biotech enrol first patient in RRMS drug Phase III study - Clinical Trials Arena
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Weekly Biotech Report covering Vantrela by Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) - Market Exclusive
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Teva Pharmaceutical Industries - Crunchbase Company Profile & Funding
Prostate Cancer Therapeutics Market Competitive Landscape
CHMP says no to Laquinimod
3 Reasons to Buy Teva Right Now - TheStreet
NORMAL.DOT för Office 97
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Teva takes $215M hit from currency effects
CHMP Says No to Teva and Active Biotech's Nerventra | 2014-01-28 | FDANews | FDAnews
Active Biotech and Ipsen to present
Fortified with sentiment and cash, Active Biotech presses on | Evaluate
1 DISCIPLINARY COMMITTEE RULING February 10, 2012 AT NASDAQ OMX STOCKHOLM 2012:2 NASDAQ OMX Stockholm AB Active Biotech AB The s
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Laquinimod - Wikipedia
